Indegene Limited reported a robust performance for the financial year ended March 31, 2026. The company achieved consolidated revenue of ₹35,105 million, marking significant growth over the previous year. The Board of Directors has recommended a final dividend of ₹2.25 per equity share, reflecting strong operational cash flows and continued profitability. Key milestones included the successful integration of recent strategic acquisitions, further strengthening the company’s presence in the global healthcare and life sciences marketing landscape.
Financial Highlights for FY26
Indegene’s consolidated financial performance for the fiscal year ended March 31, 2026, demonstrated sustained growth. The company posted an annual revenue of ₹35,105 million, compared to ₹28,393 million in the previous year. Profit after tax for the year stood at ₹4,011 million. For the fourth quarter (January-March 2026), revenue reached ₹10,034 million, with a quarterly profit after tax of ₹797 million.
Strategic Dividend Recommendation
In recognition of the company’s strong financial position, the Board of Directors has recommended a final dividend of ₹2.25 per equity share (face value of ₹2 each) for the financial year ended March 31, 2026. The dividend payout is subject to approval by the shareholders during the upcoming Annual General Meeting.
Business Expansion and Acquisitions
The fiscal year was marked by significant strategic initiatives. The company successfully integrated several acquisitions, including BioPharm Parent Holding, Inc., Warn & Co Limited, and Cake Kommunikations Holdings GmbH, significantly enhancing its commercialization and transformation capabilities in the global healthcare market. These acquisitions are central to the group’s strategy of expanding its service footprint and integrated digital offerings.
Operational Reorganization
To better align with evolving market needs, the company reorganized its business segments as of October 1, 2025. Indegene now operates through two primary reportable segments: Enterprise Commercial Solutions and Enterprise Medical Solutions. This shift streamlines service delivery and allows for more focused engagement with pharmaceutical and biotech clients worldwide.
Human Capital and Future Outlook
The company continues to invest in its workforce, having granted over 600,000 Restricted Stock Units (RSUs) and 300,000 stock options during the year to eligible employees under its various incentive plans. As the organization transitions into the new fiscal year, it remains focused on leveraging its enhanced global footprint and deep domain expertise to drive sustainable value for stakeholders.
Source: BSE
